Mesenchymal Chondrosarcoma from Diagnosis to Clinical Trials
Cancers · 15.09.2023 · 15 (18) · 4581
DOI: 10.3390/cancers15184581 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 15.09.2023. Verfasst von Monika Dudzisz-Śledź und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Center, National Science Centre.
Abstract (Originalsprache)
Mesenchymal chondrosarcoma (MCS) is a rare subtype of chondrosarcoma with a poor prognosis. Although these tumors are sensitive to radiotherapy/chemotherapy, the standard treatment for localized MCS is only surgical resection, and there are no established treatment guidelines for patients with advanced and metastatic MCS. Due to the low incidence of MCS, the pathology of these tumors is still unknown, and other therapeutic options are lacking. Some studies show the potential role of the PDGF/PPI3K/AKT, PKC/RAF/MEK/ERK, and pRB pathways, and BCL2 overexpression in the pathogenesis of MCS. These findings provide an opportunity to use protein kinases and BCL2 inhibitors as potential therapy in MCS. In this review, we summarize the current knowledge about MCS diagnosis and treatment options. We show the immunological and molecular biomarkers used in the diagnosis of MCS. In addition, we discuss the known prognostic and predictive factors in MCS. Finally, we present the novel trends, including targeted therapies and ongoing clinical trials using protein kinase inhibitors and the death receptor 5 (DR5) agonist, which may be the focus of future MCS treatment studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
- Faculty of Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
- Department of Experimental Pharmacology, Mossakowski Medical Research Centre Polish Academy of Sciences, 02-106 Warsaw, Poland.
- Department of Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
- Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland.
- Institute of Genetics and Biotechnology, Faculty of Biology, University of Warsaw, 02-106 Warsaw, Poland.
ORCID-Profile: Monika Dudzisz-Śledź, Agnieszka E Zając, Dorota Sulejczak, Bartłomiej Szostakowski, Anna Szumera-Ciećkiewicz, Piotr Rutkowski, Anna M Czarnecka
Förderung
- National Science Center
- National Science Centre
Zitieren
APA
Dudzisz-Śledź, M., Kondracka, M., Rudzińska, M., Zając, A. E., Firlej, W., Sulejczak, D., Borkowska, A., Szostakowski, B., Szumera-Ciećkiewicz, A., Piątkowski, J., Rutkowski, P., & Czarnecka, A. M. (2023). Mesenchymal Chondrosarcoma from Diagnosis to Clinical Trials. Cancers, 15(18), 4581. https://doi.org/10.3390/cancers15184581
Vancouver
Dudzisz-Śledź M, Kondracka M, Rudzińska M, Zając AE, Firlej W, Sulejczak D, et al. Mesenchymal Chondrosarcoma from Diagnosis to Clinical Trials. Cancers. 2023;15(18):4581. doi:10.3390/cancers15184581
BibTeX
@article{Dudziszled2023,
author = {Dudzisz-Śledź, Monika and Kondracka, Monika and Rudzińska, Monika and Zając, Agnieszka E and Firlej, Wiktoria and Sulejczak, Dorota and Borkowska, Aneta and Szostakowski, Bartłomiej and Szumera-Ciećkiewicz, Anna and Piątkowski, Jakub and Rutkowski, Piotr and Czarnecka, Anna M},
title = {Mesenchymal Chondrosarcoma from Diagnosis to Clinical Trials},
journal = {Cancers},
year = {2023},
volume = {15},
number = {18},
pages = {4581},
doi = {10.3390/cancers15184581}
}
EUVIMED